RhumbLine Advisers’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

RhumbLine Advisers’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,832	Closed	-$10.6K	–	4403
2023 Q2	$10.6K	Sell	5,832 -43,223	-88%	-$79K	﹤0.01%	3939
2023 Q1	$65K	Buy	49,055 +2,527	+5%	+$4.13K	﹤0.01%	2896
2022 Q4	$79K	Buy	46,528 +891	+2%	+$1.13K	﹤0.01%	2919
2022 Q3	$84K	Buy	45,637 +4,564	+11%	+$13.6K	﹤0.01%	3019
2022 Q2	$126K	Buy	+41,073	New	+$251K	﹤0.01%	3013

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RhumbLine Advisers's PRDS Position: Q3 2023 in Review

RhumbLine Advisers sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 5,832 shares — an estimated $10.6K sold.

RhumbLine Advisers first reported a position in PRDS in Q2 2022 and held it in 5 quarters. The position peaked at $126K in Q2 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

RhumbLine Advisers reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
RhumbLine Advisers sold 5,832 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $10.6K.
RhumbLine Advisers first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
RhumbLine Advisers's Pardes Biosciences, Inc. Common Stock position peaked at $126K in Q2 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.